-+ 0.00%
-+ 0.00%
-+ 0.00%
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Share
Listen to the news

The Law Offices of Frank R. Cruz announces an investigation of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON HIMS & HERS HEALTH, INC. (HIMS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On July 29, 2026, the Federal Trade Commission filed a lawsuit against Hims & Hers, accusing it of sharing customers' medical information with third-party advertisers. The FTC’s criminal complaint accuses Hims of "deceptive and unlawful privacy practices," including sharing sensitive details about a patient's health with Snap and Facebook parent Meta Platforms.

On this news, shares of Hims declined $4.32 or 14.73% to close at $25.00 on July 29, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Hims securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending